Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer

Joerg Lehmann, Gerald L Denardo, Aina Yuan, Sui Shen, Robert T O'Donnell, Carol M Richman, Sally J. DeNardo

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: Radioactivity deposition in normal tissues limits the dose deliverable by radiopharmaceuticals (RP) in radioimmunotherapy (RIT). This study investigated the absorbed radiation dose in normal tissues for prostate cancer patients in comparison to breast cancer patients for 2 RPs using the monoclonal antibody (MAb) m170. Methods and Materials: 111In-DOTA-glycylglycylglycyl-l-p-isothiocyanatophenylalanine amide (GGGF)-m170 and 111In-1,4,7,10-tetraazacyclododecane-N,N′,N″,N″′-tetraacetic acid (DOTA) 2-iminothiolane (2IT)-m170, representing the same MAb and chelate with and without a cleavable linkage, were studied in 13 breast cancer and 26 prostate cancer patients. Dosimetry for 90Y was calculated using 111In MAb pharmacokinetics from the initial imaging study for each patient, using reference man- and patient-specific masses. Results: The reference man-specific radiation doses (cGy/MBq) were not significantly different for the breast and the prostate cancer patients for both RPs in all but one tissue-RP combination (liver, DOTA-2IT). The patient-specific doses had differences between the groups most of which can be related to weight differences. Conclusions: Similar normal tissue doses were calculated for two groups of patients having different cancers and genders. This similarity combined with continued careful analysis of the imaging data might allow the use of higher starting doses in early phase RIT studies.

Original languageEnglish (US)
Pages (from-to)1192-1198
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume66
Issue number4
DOIs
StatePublished - Nov 15 2006

Fingerprint

antibodies
breast
Prostatic Neoplasms
Pharmacokinetics
cancer
Monoclonal Antibodies
Breast Neoplasms
dosage
Radioimmunotherapy
Radiopharmaceuticals
Radiation
radiation
radioactivity
chelates
liver
Amides
linkages
Radioactivity
amides
dosimeters

Keywords

  • DOTA-peptide
  • Monoclonal antibody
  • Normal tissue dose
  • Radiation dose
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer. / Lehmann, Joerg; Denardo, Gerald L; Yuan, Aina; Shen, Sui; O'Donnell, Robert T; Richman, Carol M; DeNardo, Sally J.

In: International Journal of Radiation Oncology Biology Physics, Vol. 66, No. 4, 15.11.2006, p. 1192-1198.

Research output: Contribution to journalArticle

@article{f3e09efc95294e7486c89717af5de3ce,
title = "Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer",
abstract = "Purpose: Radioactivity deposition in normal tissues limits the dose deliverable by radiopharmaceuticals (RP) in radioimmunotherapy (RIT). This study investigated the absorbed radiation dose in normal tissues for prostate cancer patients in comparison to breast cancer patients for 2 RPs using the monoclonal antibody (MAb) m170. Methods and Materials: 111In-DOTA-glycylglycylglycyl-l-p-isothiocyanatophenylalanine amide (GGGF)-m170 and 111In-1,4,7,10-tetraazacyclododecane-N,N′,N″,N″′-tetraacetic acid (DOTA) 2-iminothiolane (2IT)-m170, representing the same MAb and chelate with and without a cleavable linkage, were studied in 13 breast cancer and 26 prostate cancer patients. Dosimetry for 90Y was calculated using 111In MAb pharmacokinetics from the initial imaging study for each patient, using reference man- and patient-specific masses. Results: The reference man-specific radiation doses (cGy/MBq) were not significantly different for the breast and the prostate cancer patients for both RPs in all but one tissue-RP combination (liver, DOTA-2IT). The patient-specific doses had differences between the groups most of which can be related to weight differences. Conclusions: Similar normal tissue doses were calculated for two groups of patients having different cancers and genders. This similarity combined with continued careful analysis of the imaging data might allow the use of higher starting doses in early phase RIT studies.",
keywords = "DOTA-peptide, Monoclonal antibody, Normal tissue dose, Radiation dose, Radioimmunotherapy",
author = "Joerg Lehmann and Denardo, {Gerald L} and Aina Yuan and Sui Shen and O'Donnell, {Robert T} and Richman, {Carol M} and DeNardo, {Sally J.}",
year = "2006",
month = "11",
day = "15",
doi = "10.1016/j.ijrobp.2006.06.020",
language = "English (US)",
volume = "66",
pages = "1192--1198",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer

AU - Lehmann, Joerg

AU - Denardo, Gerald L

AU - Yuan, Aina

AU - Shen, Sui

AU - O'Donnell, Robert T

AU - Richman, Carol M

AU - DeNardo, Sally J.

PY - 2006/11/15

Y1 - 2006/11/15

N2 - Purpose: Radioactivity deposition in normal tissues limits the dose deliverable by radiopharmaceuticals (RP) in radioimmunotherapy (RIT). This study investigated the absorbed radiation dose in normal tissues for prostate cancer patients in comparison to breast cancer patients for 2 RPs using the monoclonal antibody (MAb) m170. Methods and Materials: 111In-DOTA-glycylglycylglycyl-l-p-isothiocyanatophenylalanine amide (GGGF)-m170 and 111In-1,4,7,10-tetraazacyclododecane-N,N′,N″,N″′-tetraacetic acid (DOTA) 2-iminothiolane (2IT)-m170, representing the same MAb and chelate with and without a cleavable linkage, were studied in 13 breast cancer and 26 prostate cancer patients. Dosimetry for 90Y was calculated using 111In MAb pharmacokinetics from the initial imaging study for each patient, using reference man- and patient-specific masses. Results: The reference man-specific radiation doses (cGy/MBq) were not significantly different for the breast and the prostate cancer patients for both RPs in all but one tissue-RP combination (liver, DOTA-2IT). The patient-specific doses had differences between the groups most of which can be related to weight differences. Conclusions: Similar normal tissue doses were calculated for two groups of patients having different cancers and genders. This similarity combined with continued careful analysis of the imaging data might allow the use of higher starting doses in early phase RIT studies.

AB - Purpose: Radioactivity deposition in normal tissues limits the dose deliverable by radiopharmaceuticals (RP) in radioimmunotherapy (RIT). This study investigated the absorbed radiation dose in normal tissues for prostate cancer patients in comparison to breast cancer patients for 2 RPs using the monoclonal antibody (MAb) m170. Methods and Materials: 111In-DOTA-glycylglycylglycyl-l-p-isothiocyanatophenylalanine amide (GGGF)-m170 and 111In-1,4,7,10-tetraazacyclododecane-N,N′,N″,N″′-tetraacetic acid (DOTA) 2-iminothiolane (2IT)-m170, representing the same MAb and chelate with and without a cleavable linkage, were studied in 13 breast cancer and 26 prostate cancer patients. Dosimetry for 90Y was calculated using 111In MAb pharmacokinetics from the initial imaging study for each patient, using reference man- and patient-specific masses. Results: The reference man-specific radiation doses (cGy/MBq) were not significantly different for the breast and the prostate cancer patients for both RPs in all but one tissue-RP combination (liver, DOTA-2IT). The patient-specific doses had differences between the groups most of which can be related to weight differences. Conclusions: Similar normal tissue doses were calculated for two groups of patients having different cancers and genders. This similarity combined with continued careful analysis of the imaging data might allow the use of higher starting doses in early phase RIT studies.

KW - DOTA-peptide

KW - Monoclonal antibody

KW - Normal tissue dose

KW - Radiation dose

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=33750343587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750343587&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2006.06.020

DO - 10.1016/j.ijrobp.2006.06.020

M3 - Article

C2 - 16965873

AN - SCOPUS:33750343587

VL - 66

SP - 1192

EP - 1198

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -